Intellia Therapeutics

Intellia Therapeutics is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in Cambridge, Massachusetts, focused on developing curative therapeutics using CRISPR/Cas9 genome editing technology. The company trades publicly on the Nasdaq under the ticker NTLA and has a notable collaboration with Regeneron Pharmaceuticals to advance treatments for serious diseases including transthyretin amyloidosis and blood disorders.